Here, based on the finding that CD93 is exclusively up-regulated on glioma-associated vascular endothelial cells (VECs), small extracellular vesicles (sEVs) were modified with insulin-like growth factor-binding protein 7 (IGFBP7), a natural ligand of CD93, to create a delivery platform that can deliver therapeutic agents to glioma-associated VECs with high efficiency. The gene discussed is IGFBP7; the disease is central nervous system cancer.